NASDAQ (usa) arrow 6715.56 -12.11 -0.18%
FTSE 100 (london) arrow 7487.96 -5.12 -0.07%
DAX (german) arrow 13465.51 235.94 1.78%
NIKKEI 225 (japan) arrow 22420.08 408.47 1.86%
Hang - Seng (hong kong) arrow 28594.06 348.52 1.23%
NIFTY - 50 (india)
Straits Times (singapore) arrow 3391.61 17.53 0.52%
KOSPI (korea) arrow 2556.47 33.04 1.31%
All Ordinaries (australia) arrow 6005.30 28.90 0.48%
BOVESPA (brazil) arrow 74092.76 -215.73 -0.29%

RedHill Biopharma Ltd (F: 2RH)

 
2RH Technical Analysis
5
As on 22nd Mar 2023 2RH STOCK Price closed @ 0.10 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 1.99 & Strong Sell for SHORT-TERM with Stoploss of 3.62 we also expect STOCK to react on Following IMPORTANT LEVELS.
 
 

2RHSTOCK Price

Open 0.12 Change Price %
High 0.12 1 Day -0.04 -28.57
Low 0.10 1 Week -0.06 -37.50
Close 0.10 1 Month -0.10 -50.00
Volume 40625 1 Year -3.87 -97.48
52 Week High 5.24 | 52 Week Low 0.10
 
F Germany Most Active Stocks
IMU 0.10 -99.65%
IMU 0.10 -99.65%
IMU 0.10 -99.65%
IMU 0.10 -99.65%
IMU 0.10 -99.65%
ENB 47.60 -0.92%
TEF 3.84 -0.52%
TEF 3.84 -0.52%
WHL 5150.00 -0.44%
WDI 0.05 -37.50%
 
F Germany Top Gainers Stocks
JYR 1000000.00 10000000000.00%
JYR 1000000.00 10000000000.00%
LAW 1000000.00 5000000000.00%
LAW 1000000.00 5000000000.00%
LAW 1000000.00 5000000000.00%
LAW 1000000.00 5000000000.00%
0AI 11.30 14025.00%
0AI 11.30 14025.00%
SUE1 12.60 12500.00%
HGF2 7.40 1380.00%
 
F Germany Top Losers Stocks
TINC 0.01 -99.92%
TINC 0.01 -99.92%
TINC 0.01 -99.92%
IMU 0.10 -99.65%
IMU 0.10 -99.65%
IMU 0.10 -99.65%
IMU 0.10 -99.65%
IMU 0.10 -99.65%
IMU 0.10 -99.65%
LDB 1.71 -92.57%
 
 
2RH
Daily Charts
2RH
Intraday Charts
Whats New @
Bazaartrend
2RH
Free Analysis
 
2RH Important Levels Intraday
RESISTANCE0.14
RESISTANCE0.13
RESISTANCE0.12
RESISTANCE0.11
SUPPORT0.09
SUPPORT0.08
SUPPORT0.07
SUPPORT0.06
 
2RH Forecast December 2024
4th UP Forecast4.4
3rd UP Forecast3.02
2nd UP Forecast2.17
1st UP Forecast1.32
1st DOWN Forecast-1.12
2nd DOWN Forecast-1.97
3rd DOWN Forecast-2.82
4th DOWN Forecast-4.2
 
2RH Weekly Forecast
4th UP Forecast2.47
3rd UP Forecast1.71
2nd UP Forecast1.24
1st UP Forecast0.77
1st DOWN Forecast-0.57
2nd DOWN Forecast-1.04
3rd DOWN Forecast-1.51
4th DOWN Forecast-2.27
 
2RH Forecast2024
4th UP Forecast10.04
3rd UP Forecast6.85
2nd UP Forecast4.88
1st UP Forecast2.91
1st DOWN Forecast-2.71
2nd DOWN Forecast-4.68
3rd DOWN Forecast-6.65
4th DOWN Forecast-9.84
 
 
2RH Other Details
Segment EQ
Market Capital 212576016.00
Sector Healthcare
Industry Drug Manufacturers-Specialty & Generic
Offical website >
 
2RH Address
2RH
 
2RH Latest News
 
Your Comments and Response on RedHill Biopharma Ltd
 
2RH Business Profile
RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focused on gastrointestinal and infectious diseases. The company promotes gastrointestinal drugs, including Movantik for opioid-induced constipation in adults with chronic non-cancer pain; Talicia for the treatment of Helicobacter pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its clinical late-stage investigational development programs include RHB-204, which is in Phase 3 study for pulmonary nontuberculous mycobacteria infections; opaganib (Yeliva), an SK2 selective inhibitor, which has completed Phase 2 study to treat patients with SARS-CoV-2 severe COVID-19 pneumonia, in Phase 1/2a study to treat advanced unresectable cholangiocarcinoma, and in investigator-sponsored Phase 2 study to treat prostate cancer; RHB-104, which is in Phase 3 studies for Crohn's disease; RHB-102 (Bekinda) that is in Phase 3 studies for acute gastroenteritis and gastritis, and has completed Phase 2 studies for irritable bowel syndrome with diarrhea; RHB-107, which is in Phase 2/3 study to treat outpatients infected with COVID-19 disease, and Phase 2a study to treat advanced unresectable cholangiocarcinoma, as well as has completed Phase 2 study to treat gastrointestinal and other solid tumors; and RHB-106, an encapsulated formulation for bowel preparation, which has completed Phase 2a study. The company was incorporated in 2009 and is headquartered in Tel Aviv, Israel. Address: 21 Ha?arba?a Street, Tel Aviv, Israel, 6473921
 
© 2005-2023 BazaarTrend.com All rights reserved.

Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service